Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
Aveo seeks FDA approval of kidney cancer drug tivozanib
The FDA accepted Aveo Oncology's new drug application for tivozanib as a treatment for advanced renal cell carcinoma. The agency is expected to decide on the drug's approval by July 28. The milestone nets Aveo $15 million from Japanese partner Astellas Pharma.
Mass High Tech (Boston) (11/29)
Or we can send an email on your behalf